Altered liver expression of genes involved in lipid and glucose metabolism in mice with partial IGF-1 deficiency: An experimental approach to metabolic syndrome

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Ita, J Rodríguez ^a   Castilla Cortazar I ^a,b   Aguirre, G A ^a   Sanchez Yago C ^c   Santos Ruiz, M Olleros ^b   Guerra Menendez L ^c   Martin Estal I ^a   Garcia Magarino M ^a   Lara Diaz V J ^a   Puche, J E ^c   Munoz U ^c  

^a ESCUELA DE MEDICINA Y CIENCIAS DE LA SALUD   (Mexico)

^b Facultad HM Hospitales de Ciencias de la Salud de la UCJC   (Spain)

^c UNIVERSIDAD SAN PABLO CEU   (Spain)

Author keywords

Acetyl CoA acyltransferase (Acaa1b); ATP citrate lyase (Acly); Dyslipidemia; Glucogenolysis; Gluconeogenesis; Glucose 6 phosphate (G6P); Growth hormone; IGF 1; Insulin resistance; Metabolic syndrome; Metabolism; Oxidative damage; Phosphoenolpyruvate carboxykinase (PEPCK); Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; GLUCOSE; LIVER ENZYME; MALONALDEHYDE; SOMATOMEDIN C; TRIACYLGLYCEROL; FATTY ACID; SOMATOMEDIN BINDING PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCOGENOLYSIS; HETEROZYGOSITY; HYPERGLYCEMIA; LIPID METABOLISM; LIPID TRANSPORT; LIPOGENESIS; LIPOLYSIS; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OXIDATIVE STRESS; PARALLEL DESIGN; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE; ANIMAL; BODY WEIGHT; CARBOHYDRATE METABOLISM; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; LIVER; METABOLISM; ORGAN SIZE;

ANIMALS; BODY WEIGHT; CARBOHYDRATE METABOLISM; DISEASE MODELS, ANIMAL; FATTY ACIDS; GLUCOSE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; LIVER; MALE; METABOLIC SYNDROME X; MICE; MICE, KNOCKOUT; ORGAN SIZE; TRIGLYCERIDES;

EID: 84944416166     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0684-9     Document Type: Article

References (57)

1. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997;336(9):633-40.
2. Clemmons DR. Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am. 2012;41:425-43 (vii-viii).
3. Clemmons DR. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest. 2004;113:25-7.
4. Yakar S, Setser J, Zhao H, Stannard B, Haluzik M, Glatt V, Bouxsein ML, Kopchick JJ, LeRoith D. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest. 2004;113:96-105.
5. Holt RI, Simpson HL, Sonksen PH. The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med. 2003;20:3-15.
6. Saukkonen T, Shojaee-Moradie F, Williams RM, Amin R, Yuen KC, Watts A, Acerini CL, Umpleby AM, Dunger DB. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes. Diabetes. 2006;55:2365-70.
7. Garcia-Fernandez M, Delgado G, Puche JE, Gonzalez-Baron S, Castilla Cortazar I. Low doses of insulin-like growth factor I improve insulin resistance, lipid metabolism, and oxidative damage in aging rats. Endocrinology. 2008;149:2433-42.
8. Castilla-Cortazar I, Garcia M, Muguerza B, Quiroga J, Perez R, Santidrian S, Prieto J. Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology. 1997;113:1682-91.
9. Liu W, Li WB, Chen ZJ, Rong ZH, Chang LW. Protective effects of IGF-1 on cortical nerve cells of neonatal rats under oxidative stress. Zhongguo Dang Dai Er Ke Za Zhi. 2014;16:203-7.
10. Mallea-Gil MS, Ballarino MC, Spiraquis A, Iriarte M, Kura M, Gimenez S, Oneto A, Guitelman M, Machado R, Miguel CM. IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome. Acta Gastroenterol Latinoam. 2012;42:20-6.
11. Moses AC. Insulin resistance and type 2 diabetes mellitus: is there a therapeutic role for IGF-1? Endocr Dev. 2005;9:121-34.
12. Malik J, Stulc T, Wichterle D, Melenovsky V, Chytilova E, Lacinova Z, Marek J, Ceska R. Hyperlipidemia is associated with altered levels of insulin-like growth factor-I. Physiol Res. 2008;57:919-25.
13. Franco C, Bengtsson BA, Johannsson G. The GH/IGF-1 axis in obesity: physiological and pathological aspects. Metab Syndr Relat Disord. 2006;4:51-6.
14. Ren J, Anversa P. The insulin-like growth factor I system: physiological and pathophysiological implication in cardiovascular diseases associated with metabolic syndrome. Biochem Pharmacol. 2015;93:409-17.
15. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am. 2004;33:351-75 (table of contents).
16. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol. 2008;28:629-36.
17. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol. 2007;49:2112-9.
18. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, Group DS. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066-76.
19. Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, Ford I, Forouhi NG, Freeman DJ, Jukema JW, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet. 2008;371:1927-35.
20. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes. 2002;51:3120-7.
21. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47:1093-100.
22. Lebovitz HE. Type 2 diabetes: an overview. Clin Chem. 1999;45:1339-45.
23. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB Sr, Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30:1219-25.
24. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, Kim KR, Lee HC, Huh KB, Cha BS. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med. 2004;164:2169-75.
25. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. 2007;92:3490-7.
26. Castilla-Cortazar I, Guerra L, Puche JE, Munoz U, Barhoum R, Escudero E, Lavandera JL. An experimental model of partial insulin-like growth factor-1 deficiency in mice. J Physiol Biochem. 2014;70:129-39.
27. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell. 1993;75:59-72.
28. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31:e15.
29. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8:118-27.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-8.
31. Guerra-Menendez L, Sadaba MC, Puche JE, Lavandera JL, de Castro LF, de Gortazar AR, Castilla-Cortazar I. IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand. J Transl Med. 2013;11:271.
32. Saydah S, Ballard-Barbash R, Potischman N. Association of metabolic syndrome with insulin-like growth factors among adults in the US. Cancer Causes Control. 2009;20:1309-16.
33. Savastano S, Di Somma C, Barrea L, Colao A. The complex relationship between obesity and the somatropic axis: the long and winding road. Growth Horm IGF Res. 2014;24:221-6.
34. Akanji AO, Smith RJ. The insulin-like growth factor system, metabolic syndrome, and cardiovascular disease risk. Metab Syndr Relat Disord. 2012;10:3-13.
35. Postic C, Dentin R, Girard J. Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab. 2004;30:398-408.
36. O'Brien RM, Granner DK. Regulation of gene expression by insulin. Physiol Rev. 1996;76:1109-61.
37. Frystyk J. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res. 2004;14:337-75.
38. Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, Tauber M, Bastide R, Rosenfeld R, Tauber JP. Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Diabetes Metab. 1996;22:245-50.
39. Bereket A, Lang CH, Wilson TA. Alterations in the growth hormone-insulin-like growth factor axis in insulin dependent diabetes mellitus. Horm Metab Res. 1999;31:172-81.
40. Latrech H, Simon A, Beltrand J, Souberbielle JC, Belmejdoub G, Polak M. Postprandial hyperglycemia corrected by IGF-I (Increlex(R)) in Laron syndrome. Horm Res Paediatr. 2012;78:193-200.
41. Lee IK. The role of pyruvate dehydrogenase kinase in diabetes and obesity. Diabetes Metab J. 2014;38:181-6.
42. Laron Z, Weinberger D. Diabetic retinopathy in two patients with congenital IGF-I deficiency (Laron syndrome). Eur J Endocrinol. 2004;151:103-6.
43. Garg N, Thakur S, McMahan CA, Adamo ML. High fat diet induced insulin resistance and glucose intolerance are gender-specific in IGF-1R heterozygous mice. Biochem Biophys Res Commun. 2011;413:476-80.
44. Beigneux AP, Kosinski C, Gavino B, Horton JD, Skarnes WC, Young SG. ATP-citrate lyase deficiency in the mouse. J Biol Chem. 2004;279:9557-64.
45. Fidaleo M, Arnauld S, Clemencet MC, Chevillard G, Royer MC, De Bruycker M, Wanders RJ, Athias A, Gresti J, Clouet P, et al. A role for the peroxisomal 3-ketoacyl-CoA thiolase B enzyme in the control of PPARalpha-mediated upregulation of SREBP-2 target genes in the liver. Biochimie. 2011;93:876-91.
46. Chen Y, Ku H, Zhao L, Wheeler DC, Li LC, Li Q, Varghese Z, Moorhead JF, Powis SH, Huang A, Ruan XZ. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation. Arterioscler Thromb Vasc Biol. 2014;34:365-76.
47. Wang W, Tong TJ. The key enzyme of cholesterol synthesis pathway: HMG-CoA reductase and disease. Sheng Li Ke Xue Jin Zhan. 1999;30:5-9.
48. Steussy CN, Critchelow CJ, Schmidt T, Min JK, Wrensford LV, Burgner JW 2nd, Rodwell VW, Stauffacher CV. A novel role for coenzyme A during hydride transfer in 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Biochemistry. 2013;52:5195-205.
49. Ness GC, Chambers CM. Feedback and hormonal regulation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase: the concept of cholesterol buffering capacity. Proc Soc Exp Biol Med. 2000;224:8-19.
50. Rokosz LL, Boulton DA, Butkiewicz EA, Sanyal G, Cueto MA, Lachance PA, Hermes JD. Human cytoplasmic 3-hydroxy-3-methylglutaryl coenzyme A synthase: expression, purification, and characterization of recombinant wild-type and Cys129 mutant enzymes. Arch Biochem Biophys. 1994;312:1-13.
51. Puche JE, Garcia-Fernandez M, Muntane J, Rioja J, Gonzalez-Baron S, Castilla Cortazar I. Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats. Endocrinology. 2008;149:2620-7.
52. Succurro E, Arturi F, Grembiale A, Iorio F, Laino I, Andreozzi F, Sciacqua A, Hribal ML, Perticone F, Sesti G. Positive association between plasma IGF1 and high-density lipoprotein cholesterol levels in adult nondiabetic subjects. Eur J Endocrinol. 2010;163:75-80.
53. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA. 1999;96:7324-9.
54. Boucher J, Mori MA, Lee KY, Smyth G, Liew CW, Macotela Y, Rourk M, Bluher M, Russell SJ, Kahn CR. Impaired thermogenesis and adipose tissue development in mice with fat-specific disruption of insulin and IGF-1 signalling. Nat Commun. 2012;3:902.
55. Lam CS, Chen MH, Lacey SM, Yang Q, Sullivan LM, Xanthakis V, Safa R, Smith HM, Peng X, Sawyer DB, Vasan RS. Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community. Arterioscler Thromb Vasc Biol. 2010;30:1479-84.
56. Troncoso R, Ibarra C, Vicencio JM, Jaimovich E, Lavandero S. New insights into IGF-1 signaling in the heart. Trends Endocrinol Metab. 2014;25:128-37.
57. Ginsberg S, Laron Z, Bed MA, Vaisman N. The obesity of patients with laron syndrome is not associated with excessive nutritional intake. Obes Res Clin Pract. 2009;3:1-52.